Sidley represented Plexxikon, a California-based drug discovery company, in a license agreement with cancer biotech company Novellus to research, develop, manufacture and (should it gain approval) exclusively sell worldwide the early clinical-stage BRAF-inhibiting compound for the treatment of solid tumors known as PLX8394. Under the terms of the agreement, Plexxikon will receive an undisclosed upfront payment, additional developmental milestones and royalty payments in exchange for the rights to PLX8394.
The Sidley team included Stephen Abreu (partner, San Francisco) and Longbo Wang (associate, Shanghai).
This website uses cookies. Analytical cookies help us improve our website by providing insight on how visitors interact with our site, and necessary cookies which the website needs to function properly.
Necessary Cookies
The website cannot function properly without these necessary cookies, and they can only be disabled by changing your browser preferences. To learn more about these cookies, how we use them on our website, and how to revise your cookie settings, please view our cookie policy.
You have successfully set your edition to United States. Would you like to make this selection your default edition?
*Selecting a default edition will set a cookie.
This website uses cookies. Analytical cookies help us improve our website by providing insight on how visitors interact with our site, and necessary cookies which the website needs to function properly.
Necessary Cookies
The website cannot function properly without these necessary cookies, and they can only be disabled by changing your browser preferences. To learn more about these cookies, how we use them on our website, and how to revise your cookie settings, please view our cookie policy.